Stockreport

Can Vir Biotechnology (VIR)'s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF that it had dosed the first patient in one of three dose-expansion cohorts in its ongoing Phase 1 trial of VIR-5500. VIR-5500 is an investigational treatment for metasta [Read more]